Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
The FDA approves blood test to guide breast cancer therapy by detecting ESR1 mutations for targeted treatment selection.
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
The FDA has approved Pfizer and Arvinas’ Veppanu, the first proteolysis-targeting chimera (PROTAC) therapy, for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations after prior ...
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...
If the crackdown on pharma’s TV ads and subsequent extension to social media has underscored anything, it’s that brands need ...
Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results